ADC Therapeutics (ADCT) News Today $2.50 +0.07 (+2.88%) Closing price 05/27/2025 03:59 PM EasternExtended Trading$2.47 -0.03 (-1.04%) As of 04:48 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADCT Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Woodline Partners LP Takes $3.85 Million Position in ADC Therapeutics SA (NYSE:ADCT)Woodline Partners LP acquired a new stake in shares of ADC Therapeutics SA (NYSE:ADCT - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 1,933,751 shares of the company's stock, valued at approximatelyMay 27 at 4:38 AM | marketbeat.comBNP Paribas Financial Markets Purchases Shares of 716,668 ADC Therapeutics SA (NYSE:ADCT)BNP Paribas Financial Markets purchased a new stake in ADC Therapeutics SA (NYSE:ADCT - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The fund purchased 716,668 shares of the company's stock, valued at approximately $1,426,000. BNP Paribas Financial MarkeMay 21, 2025 | marketbeat.comFY2025 EPS Estimates for ADCT Increased by Cantor FitzgeraldADC Therapeutics SA (NYSE:ADCT - Free Report) - Analysts at Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for ADC Therapeutics in a research note issued to investors on Thursday, May 15th. Cantor Fitzgerald analyst E. Schmidt now expects that the company will post earninMay 21, 2025 | marketbeat.comResearch Analysts Issue Forecasts for ADCT FY2025 EarningsMay 20, 2025 | americanbankingnews.comADC Therapeutics (NYSE:ADCT) Given Outperform Rating at Royal Bank of CanadaMay 18, 2025 | americanbankingnews.comAnalysts Are Upgrading ADC Therapeutics SA (NYSE:ADCT) After Its Latest ResultsMay 17, 2025 | finance.yahoo.comADC Therapeutics SA (NYSE:ADCT) Q1 2025 Earnings Call TranscriptMay 15, 2025 | msn.comADC Therapeutics ends development of ADCT-602 and unveils latest Zynlonta dataMay 15, 2025 | finance.yahoo.comOrbimed Advisors LLC Grows Position in ADC Therapeutics SA (NYSE:ADCT)Orbimed Advisors LLC boosted its holdings in shares of ADC Therapeutics SA (NYSE:ADCT - Free Report) by 31.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,968,451 shares of the cMay 15, 2025 | marketbeat.comADC Therapeutics to Present at Upcoming Investor ConferencesMay 15, 2025 | prnewswire.comADC Therapeutics signals data catalysts ahead with ZYNLONTA combinations, aims for regulatory milestones through 2025May 14, 2025 | msn.comADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European ...May 14, 2025 | gurufocus.comADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational UpdateMay 14, 2025 | gurufocus.comADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational UpdateMay 14, 2025 | prnewswire.comADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML)May 14, 2025 | prnewswire.com6ADCT : Preview: ADC Therapeutics's EarningsMay 13, 2025 | benzinga.comADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025May 8, 2025 | prnewswire.comADC Therapeutics (ADCT) Expected to Announce Quarterly Earnings on MondayADC Therapeutics (NYSE:ADCT) will be releasing its Q1 2025 earnings before the market opens on Monday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-5-adc-therapeutics-sa-stock/)April 30, 2025 | marketbeat.comADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025April 28, 2025 | prnewswire.comHC Wainwright Analysts Boost Earnings Estimates for ADCTADC Therapeutics SA (NYSE:ADCT - Free Report) - Stock analysts at HC Wainwright boosted their Q1 2025 EPS estimates for shares of ADC Therapeutics in a research report issued on Monday, March 31st. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.39) per shareApril 5, 2025 | marketbeat.comShort Interest in ADC Therapeutics SA (NYSE:ADCT) Drops By 14.0%ADC Therapeutics SA (NYSE:ADCT - Get Free Report) saw a large decrease in short interest in the month of March. As of March 15th, there was short interest totalling 4,560,000 shares, a decrease of 14.0% from the February 28th total of 5,300,000 shares. Based on an average daily volume of 514,400 shares, the days-to-cover ratio is currently 8.9 days. Approximately 6.0% of the company's shares are short sold.April 4, 2025 | marketbeat.comADC Therapeutics Makes Grants to New Employees Under Inducement PlanApril 1, 2025 | prnewswire.comADC Therapeutics (NYSE:ADCT) Price Target Lowered to $7.00 at GuggenheimGuggenheim dropped their price objective on shares of ADC Therapeutics from $10.00 to $7.00 and set a "buy" rating for the company in a research note on Monday.April 1, 2025 | marketbeat.comHC Wainwright Reaffirms Buy Rating for ADC Therapeutics (NYSE:ADCT)HC Wainwright reissued a "buy" rating and issued a $8.00 target price on shares of ADC Therapeutics in a research report on Monday.April 1, 2025 | marketbeat.comADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare ConferenceApril 1, 2025 | prnewswire.comQ4 2024 ADC Therapeutics SA Earnings Call TranscriptApril 1, 2025 | gurufocus.comADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Highlights: Navigating Challenges and ...April 1, 2025 | gurufocus.comADC Therapeutics (NYSE:ADCT) Announces Quarterly Earnings ResultsADC Therapeutics (NYSE:ADCT - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.06. The business had revenue of $19.00 million during the quarter, compared to analyst estimates of $19.01 million.March 29, 2025 | marketbeat.comADC Therapeutics SA (NYSE:ADCT) Q4 2024 Earnings Call TranscriptMarch 29, 2025 | msn.comADC Therapeutics reports Q4 adjusted EPS (25c) vs. (97c) last yearMarch 28, 2025 | markets.businessinsider.comADC Therapeutics targets $600M–$1B in peak ZYNLONTA revenue amid expansion into DLBCL marketMarch 27, 2025 | msn.comADC Therapeutics SA (ADCT) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comADC Therapeutics reports Q4 results, beats on EPS but misses revenueMarch 27, 2025 | investing.comADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational UpdateMarch 27, 2025 | prnewswire.comADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025March 25, 2025 | prnewswire.comADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on ...March 20, 2025 | gurufocus.comADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025March 20, 2025 | prnewswire.comADC Therapeutics SA (NYSE:ADCT) Shares Purchased by Platinum Investment Management Ltd.Platinum Investment Management Ltd. boosted its holdings in ADC Therapeutics SA (NYSE:ADCT - Free Report) by 11.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,612,556 shares of the company's stock after buying an additional 168,040 sMarch 20, 2025 | marketbeat.comADC Therapeutics (NYSE:ADCT) Earns Overweight Rating from Cantor FitzgeraldCantor Fitzgerald reiterated an "overweight" rating on shares of ADC Therapeutics in a research report on Friday.March 8, 2025 | marketbeat.comADC Therapeutics (ADCT) to Release Earnings on WednesdayADC Therapeutics (NYSE:ADCT) will be releasing earnings before the market opens on Wednesday, March 12, Financial Modeling Prep reports.March 5, 2025 | marketbeat.comNewly launched Seattle cancer therapy startup Callio Therapeutics raises $187MMarch 4, 2025 | msn.comADC Therapeutics price target raised to $8 from $6 at StephensFebruary 24, 2025 | markets.businessinsider.comStephens Forecasts Strong Price Appreciation for ADC Therapeutics (NYSE:ADCT) StockStephens lifted their price target on ADC Therapeutics from $6.00 to $8.00 and gave the company an "overweight" rating in a research note on Monday.February 24, 2025 | marketbeat.comADC Therapeutics SA (NYSE:ADCT) Short Interest Down 6.2% in JanuaryADC Therapeutics SA (NYSE:ADCT - Get Free Report) was the target of a significant decrease in short interest during the month of January. As of January 31st, there was short interest totalling 4,860,000 shares, a decrease of 6.2% from the January 15th total of 5,180,000 shares. Based on an average trading volume of 921,800 shares, the days-to-cover ratio is presently 5.3 days.February 18, 2025 | marketbeat.comOrbimed Advisors LLC Reduces Stake in ADC Therapeutics SAFebruary 15, 2025 | gurufocus.comADCT stock touches 52-week low at $1.42 amid market challengesFebruary 12, 2025 | msn.comADCT Stock Touches 52-Week Low at $1.61 Amid Market ChallengesJanuary 30, 2025 | msn.comADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech ConferenceJanuary 30, 2025 | prnewswire.comADCT stock touches 52-week low at $1.66 amid market challengesJanuary 23, 2025 | msn.comEquities Analysts Issue Forecasts for ADCT FY2025 EarningsADC Therapeutics SA (NYSE:ADCT - Free Report) - Analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for ADC Therapeutics in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt expects that the company will post earnings of ($1.66) perJanuary 22, 2025 | marketbeat.com Get ADC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter. Email Address ADCT Media Mentions By Week ADCT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADCT News Sentiment▼1.171.03▲Average Medical News Sentiment ADCT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADCT Articles This Week▼12▲ADCT Articles Average Week Get ADC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RCUS News ARDX News NTLA News PAHC News COLL News CVAC News WVE News SYRE News AVDL News SNDX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ADCT) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredTrump Quietly Planning $15 Trillion Crypto ShockerMost investors are still unaware, but I believe a new White House action may have quietly opened the floodgate...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADC Therapeutics SA Please log in to your account or sign up in order to add this asset to your watchlist. Share ADC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ADCT Stock Free ADCT Stock Alerts